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A B S T R A C T   
Background: Vaccine induced immune mediated thrombocytopenia or VITT, is a recent and rare phenomenon of 
thrombosis with thrombocytopenia, frequently including cerebral venous thromboses (CVT), that has been 
described following vaccination with adenovirus vaccines ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2⋅S 
Johnson and Johnson (Janssen/J&J). The evaluation and management of suspected cases of CVT post COVID-19 
vaccination are critical skills for a broad range of healthcare providers. 
Methods: A collaborative comprehensive review of literature was conducted among a global group of expert 
neurologists and hematologists. 
Findings: Strategies for rapid evaluation and treatment of the CVT in the context of possible VITT exist, including 
inflammatory marker measurements, PF4 assays, and non-heparin anticoagulation.   
1. Introduction 
Recent rare reports of thrombosis with thrombocytopenia, including 
cerebral venous thromboses (CVT) (also known as cerebral venous sinus 
thromboses (CVST)), have been described following immunization with 
adenovirus-vector COVID-19 vaccines ChAdOx1 nCOV-19 (AstraZe-
neca) and Ad26.COV2⋅S Johnson and Johnson (Janssen/J&J) [1,2]. 
These reports may have global effects on vaccine implementation and 
present new challenges to vaccine surveillance and safety monitoring 
worldwide. Adenoviral vaccines have become the preferred vaccine for 
middle and low income countries as they do not require ultra-cold chain 
storage requirements and for Ad26.COV2⋅S specifically, its single dosing 
schedule [3]. Thus, these vaccines have become the cornerstone for 
COVID-19 Vaccines Global Access (COVAX), a global initiative to pro-
vide equitable access to vaccines, with 500 million doses of Ad26. 
COV2⋅S and 170 million doses of ChAdOx1 nCOV-19 booked by the 
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program [4,5]. 
Importantly, new onset headache, one of the non-specific but car-
dinal features of CVT, is seen in up to 67% of individuals during the 
initial few days after any COVID-19 vaccination [6,7]. Therefore, whilst 
over-investigation of all patients with a post-vaccination headache is 
unnecessary and not feasible, both delayed diagnosis and treatment of 
CVT risk significant individual morbidity and mortality. Correct and 
timely diagnosis of CVT in post-COVID-19 vaccinated patients, as well as 
the evaluation and management approach in suspected cases of vaccine- 
induced immune-mediated thrombocytopenia with thromboses (VITT), 
are critical skills for a broad range of healthcare providers. Here, we 
review CVT in the context of possible VITT, provide practical guidance 
on clinical approaches and explore unanswered mechanistic and man-
agement questions regarding the possible relationship between the 
adenovirus vector COVID-19 vaccinations and VITT. 
Overall, CVT is a rare form of stroke (0.5% to 1% of all strokes prior 
to the COVID-19 pandemic) that occurs when the cerebral venous sinus 
system or the smaller draining veins are completely or partially occluded 
[8]. Occlusion of a venous structure causes physiologic backflow in 
venous drainage, leading to localized brain edema, seizures, and in some 
cases, brain infarction and/or intracerebral hemorrhage (ICH) [8,9]. 
CVT can also result in venous hypertension, decreased CSF absorption 
and consequently, increased intracranial pressure (ICP) [10]. In contrast 
to arterial strokes, venous strokes are more common in young adults, 
with a median age of 39 years (range 16–85) and are three times more 
common in women than men [11]. Predisposing causes of CVT are 
multiple, including both genetic and non-genetic risk factors [12,13] 
(Table 1). With regards to the risk of CVT in the context of SARS-CoV-2 
infection, a recent report found an incidence of 8.8 per 10,000, with a 
male predominance and average age of 49 years (95% CI, 36–62 years) 
[14]. In a review of electronic health record system data from 59 US 
health centers, the incidence of CVT after COVID-19 was 42.8 per 
million, which was significantly higher than the incidence in matched 
patients with influenza and or after SARS-CoV-2 mRNA vaccination, 
with a relative risk of 3.81 95% CI 1.56–9.41, P < 0.001) and 6.67 95% 
CI 1.98–22.43, P < 0.001, respectively [15]. Analysis of the TriNetX 
global health collaborative clinical research platform including 667,551 
COVID-19 patients and 65,796,480 non-COVID-19 patients found the 
odds of developing CVT were 41 times higher in COVID-19 patients than 
among non-COVID-19 patients [16]. [Thus, evidence supports SARS- 
CoV2 infection itself as a significant increased risk of CVT, and thus 
regional recommendations have emphasized that individuals at risk of 
COVID-19 overall benefit from COVID-19 vaccination. 
2. Cerebral Venous Thrombosis in the context of SARS-CoV-2 
vaccination (Table 2) 
As of May 25th 2021, almost 1.5 billion SARS-COV-2 vaccine doses 
have been administered worldwide, with over 10.3 million doses of 
Ad26.COV2⋅S vaccine given in the US and more than 34 million doses of 
ChAdOx1 nCOV-19 given in the UK [17–19]. Close monitoring for 
possible vaccine adverse events following immunization has occurred 
both during clinical trials, and via public health surveillance systems in 
the post-marketing period. Reports of thrombotic events to public health 
surveillance programs prompted recent investigation. After review by 
the European Medicine Agency (EMA) safety committee on events in the 
context of ChAdOx1 nCOV-19 vaccine, the EMA concluded that the 
vaccine may be associated with very rare cases of blood clots associated 
with thrombocytopenia, though the report emphasized the overall sig-
nificant benefit of COVID-19 vaccination [20]. On the 4th of April 2021, 
169 cases of CVT and 53 cases of splanchnic vein thrombosis post- 
vaccination were captured by EMA [20] The number of cases was 
4.94 (95% CI: 2.63–8.45) times higher than expected with a case fatality 
rate (CFR) of 22.6%. Thrombocytopenia was reported in 53.2% of cases 
though there is a lack of confirmation of platelet values, as well as other 
risk factors for CVT, in many of the reported cases [21]. On April 22nd, 
the United Kingdom's Medicines and Healthcare products Regulatory 
Agency (MHRA) reported 171 major blood clots, with CVT in 77 cases 
(some overlapping with the cases captured by the EMA), a rate of 7.9 
patients per million doses administered [22]. Up to May 12th, overall 
309 cases of VITT were reported, of whom 116 had a cerebral venous 
sinus thrombosis, an overall rate of VITT of 12.3 per million doses and 
with case fatality rate of 18% [22]. The majority were women under 60 
years old, but given differing vaccine distribution across populations, 
ultimate conclusions regarding age predisposition have not yet been 
determined [20,22]. The British Society of Hematology has noted that 
there is no current evidence that individuals with known thrombotic risk 
factors are at higher risk of developing immune complications related to 
the ChAdOx1 nCOV-19 vaccine [23]. 
On April 13th, 50 days after Emergency Use Authorization (EUA) 
approval for Ad26.COV2⋅S vaccine use, the United States (US) Centers 
for Disease Control and Prevention (CDC) and Federal Drug Adminis-
tration (FDA) recommended a pause in the use of Ad26.COV2⋅S vaccine, 
in the context of 6 reports of CVT of more than 6.8 million doses 
administered [24,25]. [24,25]. As of May 7th, the CDC reported 19 or 28 
TTS cases with CVT after Ad26.COV2⋅S vaccine. Among the 28 cases of 
TTS, median age was 40 years (range 18–59 years), 22 (79%) were in 
women. [26] On April 21st, six additional cases of CVT with thrombo-
cytopenia were reported. The 12 cases occurred in women between the 
ages of 18 and 60 years, with 11 women younger than 50 years old. The 
cases closely resembled those described after ChAdOx1 nCOV-19 
vaccination. Median time from vaccination to symptom onset was 9 
days (range 3–15 days), with all received the vaccine prior to the pause. 
Some cases had concomitant risk factors, including two patients taking 
combined oral contraceptives, one patient on hormone therapy estradiol 
patch, one on fertility treatment, 12 obese, three with diabetes, one 
current malignancy, two with active cigarette smoking use, though none 
were pregnant or in the post-partum period. All cases were negative for 
SARS-CoV-2 by nasopharyngeal polymerase chain reaction (PCR) or 
antigen testing; five individuals had evidence of past SARS-CoV-2 
infection, three by history, two by nucleocapsid serology testing only. 
In the original report of 12 cases, the most common presenting symptom 
was headache while others had had hemiparesis, aphasia, loss of con-
sciousness, and neglect. Eight patients had other thromboses, including 
two cases of portal vein thrombosis, six with internal jugular vein 
thrombosis, and three pulmonary emboli [27]. Several of the cerebral 
sinuses were affected. Reports describe 10 (53%) of individuals with 
CVT with evidence of intracerebral hemorrhage, and descriptions of 
Table 1 
Traditional risk factors associated with CVT.  
Traditional Risk factors for CVT [61] 
Genetic/acquired thrombophilia 
Genetic/acquired thrombophilia (total) 
Factor V Leiden thrombophilia 
Prothrombin Gly20210A1a mutation 
Antithrombin deficiency 
Protein S deficiency 
Protein C deficiency 
Systemic conditions 
Malignancy/myeloproliferative disorders 




Gender & Sex-specific risk factors 
Oral contraceptives 
Pregnancy and puerperium 
Hormone replacement therapy 
Miscellaneous 
Dural arteriovenous fistula 
Head or neck infections 
Anemia 
Head trauma  
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cerebral arterial involvement as well. All patients with TTS had 
thrombocytopenia with platelet nadir levels less than 50,000 in 18 
(64%) of individuals, and 24 (86%) positive for platelet factor four (PF4) 
antibodies [27]. Non-heparin anticoagulants were given in 26 (93%) of 
individuals with VITT, while heparin was given in 12 (43%), and IVIG in 
18 (64%). Three individuals have been reported to die per the latest CDC 
report. [26] One case in the Ad26.COV2⋅S phase III clinical trial was 
reported in a 25 year old male with no significant medical history, who 
developed fever and headache 9 days after vaccination, had seizure and 
cerebral hemorrhage on day 19, and was diagnosed with CVT and anti- 
PF4 positivity on day 21 [28]. 
CVT events in the context of ChAdOx1 nCOV-19 and Ad26.COV2⋅S 
vaccinations have been noted to resemble autoimmune heparin-induced 
thrombocytopenia (aHIT), as many individuals have been positive for 
PF4 antibodies [29–32]. PF4 antibodies bridge PF4 tetramers using 
endogenous non-heparin polyanions; subsequently the antibody portion 
of the PF4–aHIT-IgG complexes bind Fc gamma receptor of platelets, 
crosslinking them and triggering platelet activation [29]. Similar to HIT, 
platelet consumption leads to thrombocytopenia and the continued 
platelet and monocyte activation increases thrombin generation, 
resulting in thrombosis. Why adenoviral vector vaccines in particular, 
which are non-enveloped double stranded DNA vectors may be associ-
ated with PF4 antibody production is poorly understood (Table 3). Of 
note, for Gam-COVID-Vac (Sputnik), another recombinant adenovirus 
vaccine, clotting events have not been reported to date [33]. One 
possible mechanism, is that the biodistribution of adenoviral vaccines to 
the brain, which was seen in animal studies with ChAdOx1 nCOV-19, 
may trigger spike protein production in the brain and a subsequent 
autoimmune response with thrombosis [34]. Of note, an observational 
Table 2 
Current published reports of cerebral venous thromboses in association with vaccine-induced thrombosis-thrombocytopenia.  













Primary Peer-Reviewed Articles 
Greinacher 
et al. 2021 [29] 
Germany ChAdOx1 11 26 (22–49) 9:2 6–16 days 9* *One additional patient died of 
intracranial hemorrhage – CVT 
suspected but not confirmed. 
Wolf et al. [72] Germany ChAdOx1 3 22, 36, 46 3:0 7–17 days 3 – 
Tiede et al. [79]  Germany ChAdOx1 5 61 (41–67) 5:0 5–11 1 – 
Schulz et al. 
[31] 
Norway ChAdOx1 5 39 (32–54) 4:1 7–10 days 4 – 




ChAdOx1 23* 46 (21–77) 14:9 6–24 days 13 *One patient did present with 
thrombocytopenia and bruising but no 
thrombosis. 




ChAdOx1 2 25, 32 0:2 6 days, 9 days 2 One case also included in Scully et al. 
Castelli et al. 
2021 [74] 
Franchini et al. 
[75] 
Italy ChAdOx1 1 50 0:1 9 days 1 Both reports relate to the same patient. 
D'Agostino 
et al. [76] 
Italy ChAdOx1 1 54 1:0 12 days 1 – 
Jamme et al. 
[80]  
France ChAdOx1 1 69 1:0 11 days 1 – 
See et al. [27]  US Janssen 12 18-60 12:0 6–15 days 12 Includes case by Muir et al. 




1 48 1:0 14 days 1 Included in See et al. 






1 25 0:1 19 days 1 Phase III trial of Janssen vaccine 
Public Health and Regulatory Reports (Cases may overlap with those reported in peer-reviewed articles) 
MHRA [22] United 
Kingdom 
AZ 309 18–93 169:138 Not reported 116 Include the UK reports 
CDC [24] United 
States 
Janssen 6 18–48 6: 0 6–13 days 6 Includes report by Muir et al. 
Abbreviations: AZ = Oxford/AstraZeneca vaccine (ChAdOx1 nCOV-19). CDC = Centers for Disease Control and Prevention. MHRA = Medicines and Healthcare 
products Regulatory Agency. 
Table 3 
Some key questions on the assessment and management of confirmed cases.   
• Is CVT associated with vaccine-induced immune mediated thrombocytopenia?  
• What is the pathophysiological mechanisms of CVT and VITT?  
• Are COVID-19 vaccines associated causally with CVT risk?  
• Which vaccines are associated with the development of VITT and CVT?  
• What is the mechanism for VITT in the context of adenovirus vaccines?  
• What is the incidence of VITT?  
• What is the incidence of CVT post COVID-19 vaccinations?  
• What is the significance for positive PF4 antibodies in these cases?  
• What are patient risk factors for the development of VITT and CVT?  
• Why does the syndrome appear to cause CVT and abdominal thromboses out of 
proportion to its effect on limb and pulmonary thrombosis, which are more often 
involved in other forms of spontaneous venous thrombosis?  
• Is VITT a transitory thrombotic event or the unmasking or a long term or chronic 
prothrombotic condition?  
• Can CVT occur in the absence of possible vaccine induced immune 
thrombocytopenia?  
• What is the most effective first line treatment?  
• When should thrombectomy be considered in the context of CVT?  
• What is the optimal neurosurgical management of CVT cases in the context of 
possible VIT?  
• How should we manage severe cases unresponsive to first line treatments?  
• What proportion of patients experience recurrent thrombosis and how to stratify 
those at the highest risk of recurrence?  
• How long should we monitor the patients following discharge and are platelets a 
sufficient marker of disease activity?  
• How long should we continue oral anticoagulation?  
• How long should we continue the immunosuppressive treatments for?  
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study of 492 healthcare workers recently vaccinated with ChAdOx1 
nCOV-19 found only 6 cases of anti-PF4 antibodies with all normal 
platelet counts, highlighting the low prevalence of HIT antibodies after 
vaccination [35]. Beyond positive PF4 antibodies and thrombocyto-
penia, laboratory features often include raised D-dimer and dissemi-
nated intravascular coagulation (DIC)- like coagulopathy with tendency 
to hemorrhage [29,30,32]. 
The uniqueness of the phenotype, the consistent temporal associa-
tion with the vaccine, and the incidence exceeding expected baseline 
rates, led EMA and the UK MHRA to determine a possible causal link 
[20,22]. However, the risks versus benefits of vaccination remain 
favorable for the majority, particularly in older populations, who appear 
to be at both higher risks of morbidity and mortality from SARS-CoV2 
infection and lower risks of thrombotic events following these vac-
cines; in particular the benefits appear to outweigh the risks in the 
context of high infection rates [36] [9,10]. In line with this, multiple 
countries have modified their vaccination programs. As examples, 
ChAdOx1 nCOV-19 vaccine became restricted to those aged >40 years 
in the UK, >55 years in Canada (with some provinces, however, now 
lowering the bracket to >40), and > 60 years in Germany [37], [38,39]. 
A randomized controlled clinical of the vaccine in a pediatric population 
has also been halted [40]. On April 27th, the Advisory Committee on 
Immunization Practices in the US decided to resume use of Ad26. 
COV2⋅S vaccine in all patients over 18, emphasizing the potential impact 
of restricted use on public health implementation, especially among 
populations with barriers to vaccines that require a two-dose schedule 
[41]. The CDC did include a warning for adult women younger than 50, 
advising this group be made aware of the increased risk of thrombosis 
and be counseled on other vaccine options that have not shown this risk 
[42]. 
A population cohort study of 281,264 Danish and Norwegian in-
dividuals aged 18 to 65 who received ChAdOx1 vaccine confirmed a 
higher-than-expected rate of CVT, with an excess of 2.5 events for every 
100,000 vaccines given. The observed rate of venous thromboembolic 
events also exceeded the expected, particularly in women and in those 
aged 18–45. However, the overall number of deaths in the studied 
population was lower than anticipated, which may be due to the 
‘healthy-worker’ effect [43]. 
3. Clinical presentation 
Lack of recognition and index of suspicion commonly results in 
missed and delayed diagnosis of CVT, in the pre-COVID era. Symptoms 
reflect the location of the specific sinus or vein affected and frequently, 
multiple locations may be affected simultaneously. Headache is the most 
common manifestation of CVT. In the International Study of Cerebral 
Vein and Dural Sinus Thrombosis, headache was present in 89% of pa-
tients [11]. There is no classic pattern of headache associated with CVT; 
the headache may be generalized or focal, and often progresses over 
days to weeks [44]. It can fluctuate and severity may vary from mild to 
unbearable and is most commonly due to increased ICP or hemorrhage. 
Headache may be accompanied by papilledema and unilateral or bilat-
eral sixth nerve palsies and may be exacerbated by recumbency or 
Valsalva maneuvers, such as coughing [44]. Isolated headache, without 
evidence of increased ICP, was present in 17 (14%) of 123 consecutive 
patients with CVT in one series, demonstrating the need for a high index 
of suspicion for CVT in patients presenting with headache, particularly if 
new or otherwise unexplained, and in the appropriate risk factor profile 
[45,46]. Approximately 1/3 of patients may have isolated intracranial 
hypertension without focal signs or symptoms [47]. 
Focal neurological presentations include hemiparesis or aphasia, and 
seizures, which may be focal or generalized [11]. CVT often presents 
with bilateral deficits, particularly when the superior sagittal sinus, the 
most commonly involved venous sinus (62%), is thrombosed [45,48]. 
This characteristic may help distinguish the focal deficits of CVT from 
those of more commonly encountered arterial ischemic infarcts and 
primary intracerebral hemorrhages. The signs and symptoms of CVT are 
often progressive over days, whereas the deficit in arterial occlusions 
tends to be maximal at onset. In one international study, symptom onset 
was <48 h in about 1/3 of patients, 48 h to 30 days in 56% of patients, 
and more than 30 days in 7% of patients [45]. Seizures also occur more 
commonly with CVT (~40%) than with other stroke subtypes [45]. 
Confusion, stupor, or even coma, may occur in some patients with 
thrombosis of the internal cerebral veins that drain the thalami and 
basal ganglia [48]. This presentation may be missed, especially as CT 
scans may be unrevealing. Finally, other less common syndromes may 
occur. Thrombosis of the cavernous sinus may lead to proptosis, che-
mosis, orbital edema, diplopia, ophthalmoplegia, and facial sensory 
abnormalities due to congestion of the orbit and multiple cranial nerve 
palsies affecting nerves III, IV, V(ophthalmic and maxillary branches), 
and VI [49]. Headache, frequently retro-orbital, is also present in most 
cases. Isolated subarachnoid hemorrhage may also occur, although this 
is rare (0.8% of patients) [11]. 
4. Clinical investigation 
An initial evaluation protocol for possible thrombosis with immune 
thrombocytopenia is provided based on available evidence to date. 
Clinicians should also consult their local clinical and public health 
agency guidance, as well as those available from national and interna-
tional associations [50] (Fig. 2). Neuroimaging is required for definitive 
diagnosis of CVT and should be considered early in a young patient with 
new unusual headaches, or symptoms according to clinical presentation 
delineated above with thrombocytopenia 4–28 days after adenovirus 
SARS-CoV-2 vaccination. In addition to rapidly assessing for thrombo-
cytopenia, additional laboratory testing should include evaluation for 
coagulopathy labs including d-dimer and testing for COVID-19. 
Although a non-contrast head CT is normal in up to 30% cases 
[51,52], it remains a critical initial test that can detect indirect signs of 
venous thrombus, such as localized or diffuse cerebral edema, infarcts 
that do not respect arterial territories, and/or hemorrhage. Direct signs 
of venous thrombus, such as hyperdense sagittal sinus (dense triangle 
sign) or transverse sinus (cord sign), are subtle and less frequent, and 
regress after the first 7 to 14 days [53]. CT venograms obtained after 
administration of IV contrast are the optimal diagnostic tool in the 
identification of venous filling defects (empty delta sign) and thrombosis 
of large venous sinuses, particularly in areas or centers without access to 
MR technology, although defects may only be seen in a third of cases 
[52]. Brain MRI is more sensitive in the detection of direct and indirect 
signs of CVT [48,54], in particular when combined with Magnetic 
Resonance Venogram (MRV) [55,56] (Fig. 1). Though, MRV may also be 
falsely positive due to flow voids. The appearance of the clot on MRI 
depends on its age. During the first week, the clot appears isointense on 
T1-weighted images and hypointense on T2-weight images and Fluid- 
attenuated inversion recovery (FLAIR), mimicking the normal venous 
flow signal and can thus appear falsely reassuring. A T2-weighted 
gradient echo (GRE), or Magnetic Resonance Venogram (MRV) im-
proves diagnostic accuracy in this period, as the intraluminal thrombus 
appears hypointense [48,55,57]. A contrast-enhanced MRV is more 
sensitive than time-of-flight MRV, as low-flow areas and hypoplastic 
sinus can be problematic in the latter [58]. In the second week, the clot 
appears hyperintense on all sequences. In the chronic phase, the clot 
signal can be variable, but is typically isointense on T1 weighted im-
aging, iso− /hyperintense on T2-weighted imaging, and hypointense on 
T2-gradient echo sequences. In addition to directly identifying the 
venous clot, indirect signs such as cerebral edema, infarct, and/or 
hemorrhage can further support the diagnosis, for which diffusion- 
weighted imaging (DWI) and perfusion-weighted MRI are useful [48]. 
Conventional angiography is no longer typically required, but may be 
performed if non-invasive imaging is inconclusive, or if rare isolated 
cortical venous thrombosis is suspected. 
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5. Management strategies of possible CVT in the context of VITT 
Emerging complexities of CVT with possible VITT prompt multidis-
ciplinary management strategies, including involvement of neurology, 
hematology, neurosurgery, intensivists and neuro-endovascular teams 
(Fig. 2) [59,60]. Given that patients may deteriorate rapidly, early 
communication and transfer to medical centers which incorporate these 
specialized services is paramount. Management of complications 
including seizures and elevated intracranial pressure (ICP) is essential to 
reduce morbidity and mortality risk. 
The management strategies are subject to ongoing updates as the 
knowledge of cases advances rapidly. Many questions regarding CVT in 
the context of possible VITT remain unanswered (Table 3). Despite our 
current knowledge gaps, several strategies including immunosuppres-
sion, blood product transfusion, non-heparin anticoagulation and 
neuroradiological and neurosurgical interventions (where indicated), 
form the foundations of management and differ significantly from the 
treatment of standard CVT (Fig. 2) [60–62]. Currently, the CDC advices 
to maintain a high suspicion for symptoms that may indicate an un-
derlying thrombotic event, such as headache, abdominal pain, pete-
chiae, new or easy bruising, shortness of breath, new neurologic 
symptoms, and leg swelling [28]. In these cases, platelet counts and 
screening for ITP is advised. In the context of thrombocytopenia, the 
CDC and British Society for Hematology recommend a PF4 ELISA assay 
in tandem with consultation with a hematologist. Heparin use is 
discouraged, unless HIT testing is negative, and provisional guidelines, 
including guidance from the International Society on Thrombosis and 
Hemostasis (ISTH), recommend considering non-heparin anticoagulants 
and high-dose intravenous immunoglobulin (IVIG) [63,64]. The British 
guidelines additionally recommend abdominal ultrasound for portal or 
splanchnic vein thromboses [60]. 
Because of resemblance to aHIT, immunosuppression is the mainstay 
of treatment and should be given urgently [29,60]. The current rec-
ommendations advocate for use of intravenous immunoglobulin (IVIG) 
as the first line management. Though there is concern for thrombotic 
risk with IVIG, recent evidence from a meta-analysis and systematic 
review using adverse event data in randomized controlled trials using 
IVIG showed a lack of overall increased thromboembolic events with 
IVIG use [65]. The rationale for IVIG is the rapid inhibition of HIT an-
tibodies and reduction of platelet activation by blocking the platelet Fc 
receptor. IVIG for HIT is not included in the American Society of He-
matology 2018 guidelines, though there have been reports of its suc-
cessful use, necessitating further investigation [66]. In the context of 
early VITT, IVIG use may prevent development of thrombosis [67]. 
Therapeutic plasma exchange can also help in progressive cases or as an 
alternative or adjunct to IVIG in severe presentations [60]. Of impor-
tance, a recent population-based analysis evaluating the use of IVIG or 
therapeutic plasma exchange (TPE) in HIT, treatment with TPE or IVIG 
was associated with increased likelihood of inpatient mortality and 
major bleeding. Thus, clinicians should work closely with local experts 
to optimize management strategies [68]. Intravenous and oral cortico-
steroids have been recommended to bridge the gap if the access to IVIG 
is delayed, although it is unclear whether there is benefit from adjunc-
tive steroids with IVIG. In regions where there is no access to IVIG or 
plasma exchange, steroid use should be strongly considered. Further 
studies are required to evaluate the efficacy of steroid monotherapy, 
particularly in resource-limited settings. 
In some cases, there is DIC, with significantly raised D-dimer and low 
fibrinogen [29,60]. ISTH guidelines indicated markedly elevated D- 
dimer levels of greater than 4 times the value for venous thromboem-
bolism exclusion are highly suggestive of VITT and should be treated as 
such [64]. Serial measurements of liver function tests (LFTs) and coag-
ulation studies should be assessed in all patients with CVT. Fibrinogen 
levels should be maintained above 1.5 g/L using cryoprecipitate or 
fibrinogen concentrate [60]. The role of platelet transfusions is more 
uncertain and should be avoided in the absence of bleeding or need for 
surgical or other interventional procedures. While platelet transfusions 
are avoided, rapid progression of some cases with rising ICP may 
necessitate transfusion to enable neurosurgical intervention [60]. 
In the absence of clinical trial data, decisions on timing of anti-
coagulation are complex and best made by a multidisciplinary team, as 
cases may feature progression of thrombosis with concurrent intracra-
nial bleeding [29,31,32]. For this reason, one should consider intro-
ducing anticoagulation as soon as safe to do so, and in cases where the 
bleeding risks are higher, lower anticoagulation doses should still be 
considered [60]. Heparin-based anticoagulation should be avoided, 
though there is a lack of consistent data on outcomes in the context of 
heparin use in VITT cases [29,32,60]. Alternatives include direct 
thrombin inhibitors (e.g. argatroban and bivalirudin, if the baseline 
aPTT is normal), direct oral Xa inhibitors (e.g. apixaban, rivaroxaban) 
and indirect Xa inhibitors (fondaparinux) [29,32]. Factor Xa level 
monitoring should be considered. Patients unsuitable for or progressing 
despite anticoagulation should be considered for direct endovascular 
treatment approaches [31,69,70]. In severe cases, early discussions 
should be held with neurosurgical teams, as progression of brain edema 
and/or hemorrhage may be rapid [31,71]. Recommendations will 
evolve as epidemiological and clinical understanding of VITT expands. 
Clinicians should seek advice from local and national public health 
agencies given this rapidly evolving topic. 
Fig. 1. Neuroimaging in a cerebral venous thrombosis (CVT) case. 
A Axial T2/fluid attenuated inversion recovery sequence (FLAIR) magnetic resonance imaging (MRI) showing left anterior parietal hyperintensity. 
B Susceptibility weighted imaging (SWI) axial view MRI showing area of low susceptibility signal at left anterior parietal lobe. 
C Sagittal T1 post‑gadolinium MRI showing early subacute sinus thrombosis involving the superior sagittal sinus and left transverse sinus. 
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6. Scientific questions and future directions 
There are certainly many unanswered questions regarding CVT 
following SARS-CoV2 vaccination, particularly in association with VITT 
(Table 3). Further research is required to define the incidence of VITT, 
potential contributing factors, any early risk factors and management for 
this rare condition. Identification of the specific component of the 
adenoviral vaccines that may trigger this syndrome is vital. One key 
unsolved question is why this syndrome appears to cause CVT and 
abdominal thromboses out of proportion to its effect on limb and pul-
monary thrombosis, which are more often involved in other forms of 
spontaneous venous thrombosis. 
7. Conclusion 
Ongoing close monitoring and reporting of conditions by frontline 
clinicians is imperative to local and national public health agencies. 
Strategies for rapid treatment of CVT and VITT-CVT are outlined here, 
Fig. 2. Evaluation and management algorithm for cerebral venous thromboses in the context of possible vaccine induced thrombocytopenia.  
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though information is evolving, and improved understanding of the 
pathophysiology will further inform future guidance. Working groups in 
several professional societies and public health agencies, including the 
World Health Organization, have gathered experts to provide further 
guidance rapidly. A particular challenge will be around assessment, 
monitoring, and management for CVT in resource-limited settings, 
where specialized clinical services, laboratory and imaging capacity, as 
well as treatments, are very much limited. Beyond diagnosis and man-
agement, public health specialists and implementation scientists should 
explore ways to enhance public and professional education to reduce the 
impact of CVT on the individual's health and vaccination efforts. It is 
important to recognize that the risk of CVT from COVID-19 greatly 
outweighs the risk from COVID-19 vaccines which are overall safe, very 
effective, and critical to ending the acute phase of this global pandemic. 
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